Kaltura (NASDAQ:KLTR) reported first-quarter 2026 results that exceeded its guidance for revenue and adjusted EBITDA, while also generating positive operating cash flow in a first quarter for the first time in the company’s history, executives said on the company’s earnings call.
Co-founder, Chairm
aTyr Pharma (NASDAQ:ATYR) said it plans to conduct a new Phase III trial of efzofitimod in pulmonary sarcoidosis after receiving feedback from the U.S. Food and Drug Administration at a recent Type C meeting.
President and CEO Dr. Sanjay Shukla said the meeting, held in mid-April with official minu
Health Catalyst (NASDAQ:HCAT) reported first-quarter 2026 results that topped its own expectations, while management outlined a broad restructuring plan aimed at simplifying the company’s operating model, reducing costs and shifting the business further toward technology-led growth.
Chief Executive
Hf Foods Group (NASDAQ:HFFG) reported higher first-quarter revenue and improved profitability as management said volume growth, cost controls and operational changes helped offset pressure from product mix, tariffs and rising fuel costs.
The Asian specialty food distributor posted net revenue of $3
Harmonic (NASDAQ:HLIT) reported a stronger-than-expected first quarter for fiscal 2026, driven by sharp growth in its broadband business and broader adoption beyond its largest customers, according to comments from executives on the company’s earnings call.
President and CEO Nimrod Ben-Natan said t
iHeartMedia (NASDAQ:IHRT) reported first-quarter 2026 revenue growth that met management’s expectations, while adjusted earnings came in modestly below guidance as the company cited timing of non-cash marketing expenses and softer March advertising demand.
Chairman and CEO Bob Pittman said consolid
GoPro (NASDAQ:GPRO) said it has begun a strategic review after receiving inbound merger-and-acquisition interest tied to its exploration of defense and aerospace opportunities, while reporting lower first-quarter revenue and a wider loss.
Founder and CEO Nicholas Woodman said on the company’s first
Halozyme Therapeutics (NASDAQ:HALO) reported a sharp increase in first-quarter 2026 revenue and earnings, driven by continued growth in royalties from its ENHANZE drug-delivery platform, and announced a new $1 billion share repurchase authorization.
On the company’s earnings call, President and CEO
Join us as we dive into Republic Services (RSG) and uncover why this stock is rated so highly by our experts. Could it be the investment opportunity you've been waiting for?
